Transgene Financials
| TNG Stock | EUR 1.23 0.03 2.38% |
Transgene |
Understanding current and past Transgene Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Transgene's financial statements are interrelated, with each one affecting the others. For example, an increase in Transgene's assets may result in an increase in income on the income statement.
The data published in Transgene's official financial statements typically reflect Transgene's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Transgene's quantitative information. For example, before you start analyzing numbers published by Transgene accountants, it’s essential to understand Transgene's liquidity, profitability, and earnings quality within the context of the Healthcare space in which it operates.
Please note, the presentation of Transgene's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Transgene's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Transgene's management manipulating its earnings.
Transgene Stock Summary
Transgene competes with Hydrogen Refueling, OSE Pharma, Biophytis, and Abivax SA. Transgene SA, a biotechnology company, designs, develops, and produces therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company was founded in 1979 and is headquartered in Illkirch-Graffenstaden, France. TRANSGENE operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 132 people.| Foreign Associate | Australia |
| Instrument | France Stock View All |
| Exchange | Euronext Paris |
| ISIN | FR0005175080 |
| Business Address | 400, Boulevard Gonthier |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | NYSE Composite |
| Website | www.transgene.fr |
| Phone | 33 3 88 27 91 00 |
| Currency | EUR - Euro |
You should never invest in Transgene without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Transgene Stock, because this is throwing your money away. Analyzing the key information contained in Transgene's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Transgene Key Financial Ratios
Transgene's financial ratios allow both analysts and investors to convert raw data from Transgene's financial statements into concise, actionable information that can be used to evaluate the performance of Transgene over time and compare it to other companies across industries.Transgene Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Transgene's current stock value. Our valuation model uses many indicators to compare Transgene value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Transgene competition to find correlations between indicators driving Transgene's intrinsic value. More Info.Transgene SA is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Transgene by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Transgene's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Transgene SA Systematic Risk
Transgene's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Transgene volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Transgene SA correlated with the market. If Beta is less than 0 Transgene generally moves in the opposite direction as compared to the market. If Transgene Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Transgene SA is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Transgene is generally in the same direction as the market. If Beta > 1 Transgene moves generally in the same direction as, but more than the movement of the benchmark.
Transgene June 12, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Transgene help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Transgene SA. We use our internally-developed statistical techniques to arrive at the intrinsic value of Transgene SA based on widely used predictive technical indicators. In general, we focus on analyzing Transgene Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Transgene's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.71 | |||
| Information Ratio | 0.0686 | |||
| Maximum Drawdown | 18.19 | |||
| Value At Risk | (3.76) | |||
| Potential Upside | 5.65 |
Complementary Tools for Transgene Stock analysis
When running Transgene's price analysis, check to measure Transgene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transgene is operating at the current time. Most of Transgene's value examination focuses on studying past and present price action to predict the probability of Transgene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transgene's price. Additionally, you may evaluate how the addition of Transgene to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Stocks Directory Find actively traded stocks across global markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |